Global Insulin Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2031

Insulin Market Analysis

The insulin market is a crucial segment of the global diabetes care industry, driven by the rising prevalence of diabetes, particularly Type 1 and Type 2. With advancements in technology and a growing focus on personalized medicine, the market is witnessing a shift towards innovative insulin formulations and delivery devices, including pens, pumps, and smart insulin systems. Recent developments highlight significant progress, such as the acceptance of new biologics and the introduction of rapid-acting insulin analogs, enhancing treatment efficacy and patient compliance. In addition, the increasing demand for insulin in emerging markets, coupled with improved healthcare infrastructure, presents substantial growth opportunities. The emphasis on continuous glucose monitoring and integrated diabetes management systems further propels market growth. Overall, the insulin market is poised for sustained expansion, driven by ongoing innovations and a heightened focus on effective diabetes management.

Insulin Market Size

The global insulin market size was valued at USD 19.97 billion in 2023 and is projected to reach USD 27.12 billion by 2031, with a CAGR of 3.90% during the forecast period of 2024 to 2031. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Insulin Market Trends

“Innovations in Biosimilar Insulins”

The insulin market is evolving rapidly, influenced by rising diabetes prevalence and advancements in treatment technologies. Innovations such as biosimilar insulins and smart delivery devices are enhancing patient compliance and outcomes. One prominent trend is the increasing adoption of insulin pens and pumps, which offer convenience and precision in diabetes management. These devices enable patients to administer doses more accurately, leading to better glycemic control. Furthermore, the integration of digital health solutions, including continuous glucose monitoring systems, is reshaping diabetes care by providing real-time data for personalized treatment plans. Overall, the insulin market is characterized by ongoing innovation, focusing on improving patient experience and outcomes while addressing the growing global demand for effective diabetes management solutions.

Report Scope and Insulin Market Segmentation       

Insulin Market Definition

Insulin is a hormone produced by the pancreas that regulates blood sugar (glucose) levels in the body. It allows cells to absorb glucose from the bloodstream to use as energy or store for later use. Insulin helps maintain blood sugar levels within a narrow range, preventing hyperglycemia (high blood sugar) and hypoglycemia (low blood sugar). Its deficiency or improper function leads to conditions such as diabetes. In individuals with diabetes, insulin therapy may be required to help control glucose levels.

Insulin Market Dynamics

Drivers

• Rising Incidence of Diabetes

The rising incidence of diabetes worldwide, particularly Type 1 and Type 2 diabetes, is a significant driver of demand for insulin therapies. According to the International Diabetes Federation, the number of people living with diabetes continues to grow rapidly, with millions diagnosed each year. This surge is attributed to various factors, including sedentary lifestyles, unhealthy dietary habits, and genetic predispositions. As more individuals are diagnosed, the need for effective management solutions, including insulin, becomes critical to controlling blood glucose levels and preventing complications associated with diabetes. Consequently, healthcare providers are increasingly prescribing insulin therapies to meet the growing patient demand. This trend underscores the importance of addressing diabetes as a major public health issue and highlights the vital role of insulin in improving patient outcomes.

• Rising Healthcare Expenditure

Increased healthcare spending, especially in developing regions, plays a crucial role in enhancing access to diabetes management solutions, including insulin therapies. As countries invest more in their healthcare infrastructure, there is a greater focus on improving patient care and expanding the availability of essential medications. This uptick in spending allows for better distribution of insulin products and related diabetes management technologies, facilitating easier access for patients who need them. Moreover, improved healthcare systems can support diabetes education initiatives, empowering patients to manage their conditions more effectively. This increased accessibility promotes adherence to prescribed insulin therapies and contributes to better overall health outcomes for individuals with diabetes.

Opportunities

• Integration of Digital Health Technologies

The integration of digital health technologies, including mobile applications and continuous glucose monitoring (CGM) systems, offers significant opportunities for the development of comprehensive diabetes management solutions that incorporate insulin therapy. These technologies enable patients to track their blood glucose levels in real time, allowing for more precise adjustments to insulin dosages based on their daily activities and dietary choices. Mobile apps can facilitate seamless communication between patients and healthcare providers, fostering better adherence to treatment plans and promoting proactive management of diabetes. In addition, the data collected through these digital tools can help healthcare professionals tailor insulin regimens to individual patient needs, ultimately improving outcomes. As digital health continues to evolve, it presents a transformative opportunity to enhance diabetes care and optimize insulin therapy for better patient quality of life.

• Innovative Delivery Systems

The growing demand for convenient and user-friendly insulin delivery devices, such as smart insulin pens and inhaled insulin, presents significant opportunities for product development and market differentiation. Patients increasingly seek solutions that simplify the process of administering insulin while improving accuracy and reducing discomfort. Smart insulin pens, equipped with digital features such as dosage tracking and reminders, enhance adherence and empower users to manage their diabetes more effectively. Similarly, inhaled insulin offers a needle-free alternative that caters to those apprehensive about injections, providing an appealing option for many patients. As manufacturers focus on innovation to meet these evolving preferences, they can capitalize on the market's demand for advanced delivery systems. This shift fosters patient satisfaction and creates a competitive edge for companies willing to invest in the development of these cutting-edge solutions.

Restraints/Challenges

• High Costs of Insulin

The rising prices of insulin and related products present substantial barriers for patients, significantly impacting their ability to manage diabetes effectively. As insulin costs increase, many individuals may find themselves unable to afford their necessary medications, leading to decreased adherence to prescribed therapies. This non-adherence can result in poorly controlled blood glucose levels, heightening the risk of severe complications such as cardiovascular disease, neuropathy, and kidney damage. Furthermore, the financial strain may force patients to make difficult choices between their medications and other essential needs, exacerbating health disparities. As a consequence, the overall burden of diabetes management increases, placing additional strain on healthcare systems. Addressing the issue of high insulin prices is crucial to ensure that all patients have access to the necessary treatments for effective diabetes management and improved health outcomes.

•  Shortage Limited Treatment Options

Despite significant advancements in diabetes care, the range of effective treatment options for insulin therapy remains relatively narrow, posing a substantial restraint on the market. Many patients with Type 1 and Type 2 diabetes rely primarily on traditional insulin formulations, which can limit their ability to tailor treatment plans to their specific needs. This lack of diversity in treatment options can hinder effective blood glucose management, leading to dissatisfaction and decreased adherence to prescribed therapies. Furthermore, patients may struggle to find suitable alternatives when they experience adverse effects or inadequate responses to existing insulin products. Consequently, this limitation can restrict patient choice and flexibility in managing their condition, ultimately impacting overall health outcomes. Expanding the variety of effective treatment options is essential to enhance patient empowerment and optimize diabetes management strategies.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Insulin Market Scope

The market is segmented on the basis of product type, source, disease type, delivery devices, end users. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product Type

• Intermediate Acting Insulin
• Short Acting Insulin
• Rapid Acting Insulin
• Long Acting Insulin

Source

• Human Recombinant Insulin
• Insulin Analogs

Disease Type

• Type 1 Diabetes
• Type 2 Diabetes
• Gestational Diabetes
• Prediabetes

Delivery Devices

• Syringes
• Pens
• Pumps
• Others

End Users

• Home Healthcare
• Hospitals
• Over The Counter (OTC)
• Clinics
• Others

Insulin Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, product type, source, disease type, delivery devices, end users as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America leads the insulin market, primarily driven by the high prevalence of diabetes among its population. In addition, the region is characterized by robust research activities aimed at advancing diabetes treatment, coupled with a diverse array of manufacturers contributing to the market. This combination of factors solidifies North America's position as a dominant force in the insulin sector.

Asia-Pacific region is projected to experience the highest growth rate in the insulin market from 2024 to 2031, driven by an increasing geriatric population and a rising incidence of diabetes. In addition, heightened awareness of the benefits of insulin therapy among the public, coupled with substantial investments in developing advanced and innovative products, further fuels this growth. These factors collectively position Asia-Pacific as a key player in the expanding insulin market.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.  

Insulin Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Insulin Market Leaders Operating in the Market Are:

• Sanofi (France)
• Novo Nordisk A/S (Denmark)
• Eli Lilly and Company (U.S.)
• Biocon (India)
• Julphar (UAE)
• Ypsomed AG (Switzerland)
• BD (U.S.)
• Wockhardt Ltd. (India)
• B. Braun SE (Switzerland)
• Biodel AG Inc. (U.S.)
• Shanghai Fosun Pharmaceutical（Group）Co., Ltd.  (China)
• Tonghua Dongbao Pharmaceutical Co., Ltd. (China)

Latest Developments in Insulin Market

• In September 2023, Novo Nordisk announced a partnership with Aspen Pharmacare Holdings Limited and Aspen SA Operations (Pty) Ltd to establish human insulin production in South Africa. This collaboration aims to enhance local manufacturing capabilities, ensuring a more reliable supply of insulin to meet the growing demand in the region. By investing in local production, the partnership seeks to improve access to insulin therapies for patients in South Africa
• In November 2022, the U.S. FDA granted approval for Rezvoglar, marking it as the second interchangeable biosimilar of insulin glargine for diabetes patients. This approval aims to expand treatment options and enhance accessibility for individuals managing diabetes. By introducing Rezvoglar to the market, patients can benefit from a more affordable alternative while ensuring effective blood glucose control
• In April 2022, Biocon secured a three-year contract worth USD 90 million from the Ministry of Health in Malaysia for the supply of its recombinant human insulin, Insugen. This significant contract not only reinforces Biocon's presence in the Malaysian market but also highlights the company's commitment to enhancing access to essential diabetes treatments in emerging markets. By expanding its footprint in Malaysia, Biocon aims to meet the growing demand for insulin and improve patient outcomes in the region
• In February 2022, Biocon announced a strategic collaboration with Viatris Inc. to acquire Viatris's biosimilar business. This partnership aims to bolster Biocon's research and development efforts and enhance its manufacturing capabilities. By integrating Viatris's expertise, Biocon seeks to strengthen its position in the biosimilars market and accelerate the commercialization of innovative therapies
• In November 2021, Biocon partnered with the Research Society for the Study of Diabetes in India (RSSDI) to launch a comprehensive care program aimed at supporting patients with Type 1 diabetes. This initiative not only provides valuable resources and guidance for effective diabetes management but also reinforces Biocon's commitment to improving patient outcomes. By actively engaging in such initiatives, Biocon enhances its brand image and solidifies its presence in the diabetes care market.

SKU-53107